{"id":4489,"date":"2026-07-13T10:00:36","date_gmt":"2026-07-13T08:00:36","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=4489"},"modified":"2026-07-14T10:00:47","modified_gmt":"2026-07-14T08:00:47","slug":"adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/","title":{"rendered":"Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\/IV melanoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]<a href=\"https:\/\/www.nature.com\/articles\/s41591-025-04032-8\" target=\"_blank\" rel=\"noopener\">Data from the RELATIVITY-098 trial published on Nature Medicine<\/a>\u00a0shows that the association of nivolumab plus relatlimab as adjuvant treatment doesn\u2019t improve recurrence-free survival in patients with resected melanoma compared to nivolumab alone.<\/p>\n<p>RELATIVITY-098 is a phase 3 double-blind trial where a total 1093 patients were randomized to receive adjuvant nivolumab plus relatlimab of nivolumab alone after complete resection of stage III\/IV melanoma. After a median follow-up of 26.7 months, there was no difference between groups in the primary endpoint of recurrence-free survival, therefore overall survival was not tested. Based on RELATIVITY-047, nivolumab plus relatlimab is approved for advanced melanoma; thus, translational data across the two trials were analyzed and showed a lower rate of circulating LAG-3+ T cells in the adjuvant setting of the RELATIVITY-098 trial versus advanced melanoma of RELATIVITY-047, where LAG-3+ T cells were enriched in tumor versus blood. As authors conclude, \u00abNivolumab plus relatlimab did not significantly improve recurrence-free survival compared to nivolumab in patients with resected stage III\/IV melanoma in RELATVITY-098, despite nivolumab plus relatlimab having been proven to provide benefit in patients with advanced melanoma. Translational evidence suggests that the presence of tumor may be required for the benefit of nivolumab plus relatlimab compared to nivolumab in melanoma. Nivolumab plus relatlimab remains a standard-of-care option for patients with advanced melanoma\u00bb.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;4492&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\/IV melanoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Data from<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":4492,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-4489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\/IV melanoma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\/IV melanoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T08:00:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T08:00:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_13Jul26-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Adjuvant nivolumab plus relatlimab in stage III\\\/IV melanoma\",\"datePublished\":\"2026-07-13T08:00:36+00:00\",\"dateModified\":\"2026-07-14T08:00:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/\"},\"wordCount\":296,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_13Jul26-scaled.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/\",\"name\":\"Adjuvant nivolumab plus relatlimab in stage III\\\/IV melanoma - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_13Jul26-scaled.jpg\",\"datePublished\":\"2026-07-13T08:00:36+00:00\",\"dateModified\":\"2026-07-14T08:00:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\\\/IV melanoma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_13Jul26-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_13Jul26-scaled.jpg\",\"width\":2560,\"height\":1365},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adjuvant nivolumab plus relatlimab in stage III\\\/IV melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma - Fondazione Gianni Bonadonna","description":"The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\/IV melanoma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma - Fondazione Gianni Bonadonna","og_description":"The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\/IV melanoma","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2026-07-13T08:00:36+00:00","article_modified_time":"2026-07-14T08:00:47+00:00","og_image":[{"width":2560,"height":1365,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_13Jul26-scaled.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma","datePublished":"2026-07-13T08:00:36+00:00","dateModified":"2026-07-14T08:00:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/"},"wordCount":296,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_13Jul26-scaled.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/","name":"Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_13Jul26-scaled.jpg","datePublished":"2026-07-13T08:00:36+00:00","dateModified":"2026-07-14T08:00:47+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"The phase 3 RELATIVITY-098 trial shows no added benefit with nivolumab plus relatlimab compared to nivolumab alone in stage III\/IV melanoma","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_13Jul26-scaled.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_13Jul26-scaled.jpg","width":2560,"height":1365},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Adjuvant nivolumab plus relatlimab in stage III\/IV melanoma"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=4489"}],"version-history":[{"count":4,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4489\/revisions"}],"predecessor-version":[{"id":4505,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4489\/revisions\/4505"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/4492"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=4489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=4489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=4489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}